Immuneering Announces Participation in March Investor Conferences

Rhea-AI Summary

Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology firm, announced participation in two investor conferences in March. The Cowen 43rd Annual Health Care Conference will feature a panel discussion on March 7, while the Oppenheimer 33rd Annual Healthcare Conference will include a virtual presentation on March 14. Management, including Co-Founder and CEO Ben Zeskind, will discuss the company’s pipeline and business strategy. Immuneering is focused on developing a universal-RAS therapy, with its lead product candidate, IMM-1-104, currently in a Phase 1/2a study targeting advanced solid tumors with RAS mutations.

Positive

• Participation in two significant investor conferences may enhance visibility and attract investor interest.
• Management's involvement suggests confidence in the company's strategic direction and pipeline.

Negative

• None.

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will participate in two March investor conferences to share commentary around the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder, and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.

Immuneering will participate in the following investor conferences:

Cowen 43rd Annual Health Care Conference (March 6 – 8, 2023)
Format: Panel Discussion and 1x1 Investor Meetings
Panel Discussion: Titled ‘Targeted Oncology’ on March 7 from 2:10 to 3:10 p.m. ET

Oppenheimer 33rd Annual Healthcare Conference (March 13 – 15, 2023)
Format: Virtual Presentation and 1x1 Investor Meetings
Virtual Presentation: March 14 from 2:40 to 3:10 p.m. ET

The presentations will be webcast live and archived for 90 days in the Investor Relations section of Immuneering’s website at Events & Presentations.

About Immuneering Corporation

Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, which is designed to have an accelerated cadence relative to IMM-1-104, as well as several early-stage programs. For more information, please visit www.immuneering.com

Media Contact:
Gina Nugent
Nugent Communications
617-460-3579
gina@nugentcommunications.com

Investor Contact:
Laurence Watts
Gilmartin Group
619-916-7620
laurence@gilmartinir.com

FAQ

What investor conferences is Immuneering Corporation participating in during March 2023?

Immuneering is participating in the Cowen 43rd Annual Health Care Conference from March 6-8, 2023, and the Oppenheimer 33rd Annual Healthcare Conference from March 13-15, 2023.

What is the focus of Immuneering's presentations at the investor conferences?

The focus will be on the company's pipeline, platform, and business strategy, including details about its product candidate, IMM-1-104.

When is Immuneering's panel discussion scheduled at the Cowen conference?

The panel discussion titled 'Targeted Oncology' will take place on March 7 from 2:10 to 3:10 p.m. ET.

What is the status of Immuneering's lead product candidate, IMM-1-104?

IMM-1-104 is currently in a Phase 1/2a study for patients with advanced solid tumors harboring RAS mutations.